HomeAI · summaries
Storia in 4 fonti
US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
- ·
benzinga.com
FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
- ·
endpoints.news
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine, pociredir for sickle cell disease, after feedback from the FDA that referenced a recently pulled cancer drug…
- ·
economictimes.indiatimes.com
US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy.